Tscan Therapeutics, Inc. - TCRX STOCK NEWS

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company specializing in T cell receptor (TCR)-engineered therapies, has announced participation in the Barclays Global Healthcare Conference on March 15, 2023, at 4:05 p.m. Eastern Time. This event will take place at the Loews Miami Beach Hotel. A webcast will be accessible on their website’s 'Events and Presentations' section, with an archived replay available for 90 days post-event.

The company focuses on TCR-T therapies for cancer treatment, with lead candidates TSC-100 and TSC-101 targeting hematologic malignancies and additional therapies for solid tumors.

TScan Therapeutics (TCRX) announced its Phase 1 umbrella trial for TSC-100 and TSC-101 targeting hematologic malignancies is on track, with patient enrollment expected to complete mid-2023. The company received FDA clearance for multiple INDs, including T-Plex, facilitating the use of various TCRs in solid tumor trials. Financially, TScan ended 2022 with $120 million in cash, funding operations into Q2 2024. The company reported Q4 2022 revenue of $3.1 million, an increase from $2.9 million YoY, but incurred a net loss of $18.7 million, up from $14.2 million. Total revenue for 2022 stood at $13.5 million, compared to $10.1 million in 2021.

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company, will participate in a panel discussion at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 2:10 p.m. ET in Boston, MA. The panel will focus on the development of T cell receptor (TCR)-engineered therapies for cancer treatment. A live webcast can be accessed through the Company’s website, with an archived replay available for 30 days post-event. TScan's lead candidates, TSC-100 and TSC-101, target hematologic malignancies while expanding their ImmunoBank for solid tumor therapies.

TScan Therapeutics (Nasdaq: TCRX), a biopharmaceutical company specializing in T cell receptor (TCR)-engineered T cell therapies, announced its participation in the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 3:30 p.m. Eastern Time. The presentation will be accessible via webcast on the Company’s website. TScan is developing lead therapy candidates TSC-100 and TSC-101 for treating hematologic malignancies, aiming to eliminate residual disease post-transplantation. Additionally, the company is building its ImmunoBank to provide customized therapies targeting various solid tumors.

TScan Therapeutics, Inc. (Nasdaq: TCRX) announced the FDA's clearance of its investigational new drug (IND) applications for its solid tumor program, T-Plex, along with two TCR-T products targeting MAGE-A1. T-Plex will facilitate customized combinations of TCR-T therapies, enabling personalized treatment based on tumor characteristics. The first two INDs target specific HLA types and are pivotal for advancing TScan's ImmunoBank. The company plans to initiate a multicenter Phase 1 clinical trial for various cancers by mid-2023, with initial results expected by year-end, marking significant progress in tailored cancer therapies.

TScan Therapeutics (TCRX) announced progress in its clinical pipeline, focusing on T cell receptor (TCR)-engineered therapies for cancer. The Phase 1 umbrella trial for treatments TSC-100 and TSC-101 is active across five sites, with expectations to enroll first cohorts in 1H 2023 and interim data due by year-end. The company has filed INDs for multiple TCRs targeting solid tumors and has sufficient cash to fund operations into Q2 2024. Leadership emphasized 2023 as a pivotal year, anticipating significant data readouts.

TScan Therapeutics, Inc. (Nasdaq: TCRX) announced the presentation of its Phase 1 trial design for TSC-100 and TSC-101, aimed at treating residual leukemia post-hematopoietic cell transplantation (HCT), at the 64th American Society of Hematology Annual Meeting 2022. The therapies target specific minor histocompatibility antigens and aim to reduce disease relapse. The company plans to enroll the first trial cohorts in H1 2023, with interim data expected by the end of 2023.

TScan Therapeutics, Inc. (Nasdaq: TCRX) announced participation in the 5th Annual Evercore ISI HealthCONx Conference on November 29, 2022, at 10:55 a.m. ET. The management will engage in a virtual fireside chat, which will be available via webcast on the company's website under the "Events and Presentations" section. An archived replay will be accessible for 90 days post-event. TScan is focused on developing T cell receptor-engineered therapies for cancer, targeting residual disease and relapse prevention in patients with hematologic malignancies.